Philip E Thompson

List of Publications by Year
in descending order

147	5,404	117453	98622
papers	citations	34 h-index	67 g-index

149	149	149	6815
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nature Communications, 2022, 13, 1625.	5.8	53
2	An extensional strain sensing mechanosome drives adhesion-independent platelet activation at supraphysiological hemodynamic gradients. BMC Biology, 2022, 20, 73.	1.7	7
3	Enhanced nitric oxide production by macrophages treated with a cell-penetrating peptide conjugate. Bioorganic Chemistry, 2022, 123, 105763.	2.0	2
4	Synthesis and biological evaluation of 4H-benzo[e][1,3]oxazin-4-ones analogues of TGX-221 as inhibitors of PI3KÎ². Bioorganic and Medicinal Chemistry, 2022, 69, 116832.	1.4	1
5	Design, Development, In Vitro and Preliminary In Vivo Evaluation of a Novel Photo-Angioplasty Device: Lumi-Solve. Cardiovascular Engineering and Technology, 2021, 12, 466-473.	0.7	1
6	Regioselection in the synthesis of 4-benzyltetral-1-ones and the new 4-arylbenzosuber-1-ones. Tetrahedron, 2021, 85, 132034.	1.0	1
7	A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer. Journal of Medicinal Chemistry, 2021, 64, 4841-4856.	2.9	10
8	Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide. Pharmaceutical Research, 2021, 38, 1125-1137.	1.7	6
9	Sideâ€Chain Interactions in <scp>d</scp>/<scp>l</scp> Peptide Nanotubes: Studies by Crystallography, NMR Spectroscopy and Molecular Dynamics. Chemistry - A European Journal, 2021, 27, 14489-14500.	1.7	5
10	A novel chemical biology and computational approach to expedite the discovery of new-generation polymyxins against life-threatening Acinetobacter baumannii. Chemical Science, 2021, 12, 12211-12220.	3.7	13
11	Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy. Journal of Personalized Medicine, 2021, 11, 1185.	1.1	6
12	Macrocyclic peptidomimetics as inhibitors of insulin-regulated aminopeptidase (IRAP). RSC Medicinal Chemistry, 2020, 11, 234-244.	1.7	9
13	Disrupting the platelet internal membrane via PI3KC2Î± inhibition impairs thrombosis independently of canonical platelet activation. Science Translational Medicine, 2020, 12, .	5.8	16
14	Is There an Interplay Between the Functional Domains of IRAP?. Frontiers in Cell and Developmental Biology, 2020, 8, 585237.	1.8	5
15	IRAP Inhibitors: M1-Aminopeptidase Family Inspiration. Frontiers in Pharmacology, 2020, 11, 585930.	1.6	7
16	Heterodimeric Analogues of the Potent Y1R Antagonist 1229U91, Lacking One of the Pharmacophoric C-Terminal Structures, Retain Potent Y1R Affinity and Show Improved Selectivity over Y4R. Journal of Medicinal Chemistry, 2020, 63, 5274-5286.	2.9	2
17	Synthesis and biological evaluation of a novel photo-activated histone deacetylase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127291.	1.0	8
18	Improving Membrane Permeation in the Beyond Rule-of-Five Space by Using Prodrugs to Mask Hydrogen Bond Donors. ACS Chemical Biology, 2020, 15, 2070-2078.	1.6	26

#	Article	IF	Citations
19	Structureâ€“Interaction Relationship of Polymyxins with the Membrane of Human Kidney Proximal Tubular Cells. ACS Infectious Diseases, 2020, 6, 2110-2119.	1.8	18
20	Application of a Sulfoxonium Ylide Electrophile to Generate Cathepsin X-Selective Activity-Based Probes. ACS Chemical Biology, 2020, 15, 718-727.	1.6	17
21	Substituted 1-methyl-4-phenylpyrrolidin-2-ones â€“ Fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitors. European Journal of Medicinal Chemistry, 2020, 191, 112120.	2.6	8
22	History, Chemistry and Antibacterial Spectrum. Advances in Experimental Medicine and Biology, 2019, 1145, 15-36.	0.8	22
23	Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition. Bioorganic and Medicinal Chemistry, 2019, 27, 115157.	1.4	9
24	(S)-(âˆ)-Fluorenylethylchloroformate (FLEC); preparation using asymmetric transfer hydrogenation and application to the analysis and resolution of amines. Tetrahedron, 2019, 75, 130591.	1.0	6
25	An apically located hybrid guanylate cyclaseâ€“ATPase is critical for the initiation of Ca2+ signaling and motility in Toxoplasma gondii. Journal of Biological Chemistry, 2019, 294, 8959-8972.	1.6	37
26	Structural Determinants of Isoform Selectivity in PI3K Inhibitors. Biomolecules, 2019, 9, 82.	1.8	55
27	Controlled Construction of Cyclic <scp>dâ€...</scp>/<scp>â€...l</scp> Peptide Nanorods. Angewandte Chemie - International Edition, 2019, 58, 596-601.	7.2	8
28	Controlled Construction of Cyclic <scp>dâ€...</scp>/<scp>â€...l</scp> Peptide Nanorods. Angewandte Chemie, 2019, 131, 606-611.	1.6	2
29	Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria. Cell Chemical Biology, 2018, 25, 380-391.e5.	2.5	57
30	Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	20
31	A9871 Insulin regulated aminopeptidase (irap) inhibition completely reverses age-induced cardiac fibrosis and improves cardiac function. Journal of Hypertension, 2018, 36, e57.	0.3	2
32	A Cyclic Peptide Inhibitor of the iNOSâ€“SPSB Proteinâ€“Protein Interaction as a Potential Anti-Infective Agent. ACS Chemical Biology, 2018, 13, 2930-2938.	1.6	17
33	Cyclic Hexapeptide Mimics of the LEDGF Integrase Recognition Loop in Complex with HIVâ€1 Integrase. ChemMedChem, 2018, 13, 1555-1565.	1.6	5
34	Novel pharmacological effects of a jungle ginger on prostate contractility. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-4-2.	0.0	0
35	Functional Characterization of the Unique Terminal Thioesterase Domain from Polymyxin Synthetase. Biochemistry, 2017, 56, 657-668.	1.2	8
36	Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats. Journal of Natural Products, 2017, 80, 225-229.	1.5	26

#	Article	IF	Citations
37	Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401. Journal of Natural Products, 2017, 80, 1264-1274.	1.5	27
38	Parallel and antiparallel cyclic <scp>d</scp>/<scp>l</scp> peptide nanotubes. Chemical Communications, 2017, 53, 6613-6616.	2.2	36
39	IP₃₋₄ kinase Arg1 regulates cell wall homeostasis and surface architecture to promote Cryptococcus neoformans infection in a mouse model. Virulence, 2017, 8, 1833-1848.	1.8	12
40	Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo[e][1,3]oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation. Bioorganic and Medicinal Chemistry, 2017, 25, 5531-5536.	1.4	5
41	The first total synthesis and solution structure of a polypeptin, PE2, a cyclic lipopeptide with broad spectrum antibiotic activity. Organic and Biomolecular Chemistry, 2017, 15, 7173-7180.	1.5	5
42	Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes. ACS Infectious Diseases, 2017, 3, 606-619.	1.8	25
43	Class II Phosphoinositide 3-Kinases as Novel Drug Targets. Journal of Medicinal Chemistry, 2017, 60, 47-65.	2.9	26
44	Design and Evaluation of Novel Polymyxin Fluorescent Probes. Sensors, 2017, 17, 2598.	2.1	7
45	Beta amino acidâ€modified and fluorescently labelled kisspeptin analogues with potent KISS1R activity. Journal of Peptide Science, 2016, 22, 406-414.	0.8	6
46	Redoxâ€stable cyclic peptide inhibitors of the SPSB2â€“iNOS interaction. FEBS Letters, 2016, 590, 696-704.	1.3	17
47	A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes. ACS Infectious Diseases, 2016, 2, 341-351.	1.8	16
48	Synthesis of linear and angular aryl-morpholino-naphth-oxazines, their DNA-PK, PI3K, PDE3A and antiplatelet activity. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5534-5538.	1.0	10
49	Transcriptomic Analysis of the Activity of a Novel Polymyxin against Staphylococcus aureus. MSphere, 2016, 1, .	1.3	18
50	Identification of a Cyanine-Dye Labeled Peptidic Ligand for Y₁R and Y₄R, Based upon the Neuropeptide Y C-Terminal Analogue, BVD-15. Bioconjugate Chemistry, 2016, 27, 2166-2175.	1.8	8
51	Development of single and mixed isoform selectivity PI3KÎ´ inhibitors by targeting Asn836 of PI3KÎ´. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4790-4794.	1.0	11
52	Structureâ€“Activity Studies of Î²-Hairpin Peptide Inhibitors of the Plasmodium falciparum AMA1â€“RON2 Interaction. Journal of Molecular Biology, 2016, 428, 3986-3998.	2.0	22
53	The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism. Cell, 2016, 165, 1632-1643.	13.5	126
54	Discovery and antiplatelet activity of a selective PI3KÎ² inhibitor (MIPS-9922). European Journal of Medicinal Chemistry, 2016, 122, 339-351.	2.6	31

#	Article	IF	Citations
55	Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y₄ Receptor Agonist Derived by an Olefin Metathesis Approach. Journal of Medicinal Chemistry, 2016, 59, 6059-6069.	2.9	16
56	Polymyxins: a new hope in combating Gram-negative superbugs?. Future Medicinal Chemistry, 2016, 8, 1017-1025.	1.1	74
57	Design, Synthesis, and Characterization of Cyclic Peptidomimetics of the Inducible Nitric Oxide Synthase Binding Epitope That Disrupt the Proteinâ€“Protein Interaction Involving SPRY Domain-Containing Suppressor of Cytokine Signaling Box Protein (SPSB) 2 and Inducible Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2016, 59, 5799-5809.	2.9	19
58	A Novel Serpin Regulatory Mechanism. Journal of Biological Chemistry, 2016, 291, 3626-3638.	1.6	13
59	Quantitation of Polymyxinâ€“Lipopolysaccharide Interactions Using an Image-Based Fluorescent Probe. Journal of Pharmaceutical Sciences, 2016, 105, 1006-1010.	1.6	15
60	Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines. European Journal of Medicinal Chemistry, 2016, 110, 326-339.	2.6	30
61	Propargyloxyproline Regio- and Stereoisomers for Click-Conjugation of Peptides: Synthesis and Application in Linear and Cyclic Peptides. Australian Journal of Chemistry, 2015, 68, 1365.	0.5	11
62	Identification of Potent Phosphodiesterase Inhibitors that Demonstrate Cyclic Nucleotide-Dependent Functions in Apicomplexan Parasites. ACS Chemical Biology, 2015, 10, 1145-1154.	1.6	85
63	Imaging the distribution of polymyxins in the kidney. Journal of Antimicrobial Chemotherapy, 2015, 70, 827-829.	1.3	54
64	Significant Accumulation of Polymyxin in Single Renal Tubular Cells: A Medicinal Chemistry and Triple Correlative Microscopy Approach. Analytical Chemistry, 2015, 87, 1590-1595.	3.2	54
65	Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes. Antimicrobial Agents and Chemotherapy, 2015, 59, 7489-7496.	1.4	26
66	Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-Line Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. ACS Infectious Diseases, 2015, 1, 568-575.	1.8	124
67	Class II but Not Second Classâ€”Prospects for the Development of Class II PI3K Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 3-6.	1.3	10
68	Structural basis of nSH2 regulation and lipid binding in PI3KÎ±. Oncotarget, 2014, 5, 5198-5208.	0.8	62
69	Discovery of Phosphodiesterase-4 Inhibitors: Serendipity and Rational Drug Design. Australian Journal of Chemistry, 2014, 67, 1780.	0.5	2
70	Measuring Polymyxin Uptake by Renal Tubular Cells: Is BODIPY-Polymyxin B an Appropriate Probe?. Antimicrobial Agents and Chemotherapy, 2014, 58, 6337-6338.	1.4	10
71	Synthesis, Structureâ€“Activity Relationships and Brain Uptake of a Novel Series of Benzopyran Inhibitors of Insulin-Regulated Aminopeptidase. Journal of Medicinal Chemistry, 2014, 57, 1368-1377.	2.9	46
72	A Potent Cyclic Peptide Targeting SPSB2 Protein as a Potential Anti-infective Agent. Journal of Medicinal Chemistry, 2014, 57, 7006-7015.	2.9	25

#	Article	IF	Citations
73	A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. Journal of Antibiotics, 2014, 67, 147-151.	1.0	156
74	Synthetic routes to the Neuropeptide Y Y1 receptor antagonist 1229U91 and related analogues for SAR studies and cell-based imaging. Organic and Biomolecular Chemistry, 2014, 12, 3271-3281.	1.5	10
75	Teaching â€˜Oldâ€™ Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative â€˜Superbugsâ€™. ACS Chemical Biology, 2014, 9, 1172-1177.	1.6	139
76	The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. Cell Reports, 2014, 7, 1009-1019.	2.9	34
77	Synthesis of BVD15 Peptide Analogues as Models for Radioligands in Tumour Imaging. International Journal of Peptide Research and Therapeutics, 2013, 19, 33-41.	0.9	9
78	Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. Journal of Antimicrobial Chemotherapy, 2013, 68, 2311-7.	1.3	58
79	Molecular basis for the increased polymyxin susceptibility of Klebsiella pneumoniae strains with under-acylated lipid A. Innate Immunity, 2013, 19, 265-277.	1.1	36
80	(+)-Fluorenylethylchloroformate (FLEC) â€“ improved synthesis for application in chiral analysis and peptidomimetic synthesis. Organic and Biomolecular Chemistry, 2013, 11, 2571.	1.5	5
81	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 802-805.	1.0	13
82	Pharmacology of polymyxins: new insights into an â€˜oldâ€™ class of antibiotics. Future Microbiology, 2013, 8, 711-724.	1.0	369
83	<scp>l</scp>-Aminoacyl-triazine Derivatives Are Isoform-Selective PI3KÎ² Inhibitors That Target Nonconserved Asp862 of PI3KÎ². ACS Medicinal Chemistry Letters, 2013, 4, 206-210.	1.3	27
84	Polymyxins and Analogues Bind to Ribosomal RNA and Interfere with Eukaryotic Translation in Vitro. ChemBioChem, 2013, 14, 2083-2086.	1.3	29
85	Mechanisms of PI3KÎ²-Selective Inhibition Revealed by Reciprocal Mutagenesis. ACS Chemical Biology, 2013, 8, 679-683.	1.6	19
86	Potent Inhibitors of Phosphatidylinositolâ€…3 (PI3) Kinase that have Antiproliferative Activity Only When Delivered as Prodrug Forms. ChemMedChem, 2013, 8, 914-918.	1.6	11
87	Definition of the binding mode of a new class of phosphoinositide 3-kinase Î±-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis. Biochemical Journal, 2012, 444, 529-535.	1.7	26
88	Structureâ€“activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7106-7109.	1.0	11
89	Synthesis and Pharmacological Evaluation of 4-Iminothiazolidinones for Inhibition of PI3 Kinase. Australian Journal of Chemistry, 2012, 65, 1396.	0.5	15
90	Structureâ€“activity relationships for the binding of polymyxins with human Î±-1-acid glycoprotein. Biochemical Pharmacology, 2012, 84, 278-291.	2.0	40

#	Article	IF	Citations
91	Imidazolidin-4-ones: Their Syntheses and Applications. Heterocycles, 2011, 83, 1953.	0.4	20
92	Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers. British Journal of Pharmacology, 2011, 164, 37-47.	2.7	72
93	Thiophene inhibitors of PDE4: Crystal structures show a second binding mode at the catalytic domain of PDE4D2. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7089-7093.	1.0	18
94	Active site similarity between human and Plasmodium falciparum phosphodiesterases: considerations for antimalarial drug design. Journal of Computer-Aided Molecular Design, 2011, 25, 753-762.	1.3	7
95	Thiazolidinedioneâ€Based PI3KÎ± Inhibitors: An Analysis of Biochemical and Virtual Screening Methods. ChemMedChem, 2011, 6, 514-522.	1.6	15
96	Peptide inhibitors of xenoreactive antibodies mimic the interaction profile of the native carbohydrate antigens. Biopolymers, 2011, 96, 193-206.	1.2	10
97	A facile, click chemistry-based approach to assembling fluorescent chemosensors for protein tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 329-331.	1.0	12
98	Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxinâ€“lipopolysaccharide binding interactions. Analytical Biochemistry, 2011, 409, 273-283.	1.1	45
99	Isoform-Selective Inhibition of Phosphoinositide 3-Kinase: Identification of a New Region of Nonconserved Amino Acids Critical for p110Î± Inhibition. Molecular Pharmacology, 2011, 80, 657-664.	1.0	37
100	The Phytosulfokine (PSK) Receptor Is Capable of Guanylate Cyclase Activity and Enabling Cyclic GMP-dependent Signaling in Plants. Journal of Biological Chemistry, 2011, 286, 22580-22588.	1.6	120
101	Carbohydrate-mimetic peptides: structural aspects of mimicry and therapeutic implications. Expert Opinion on Biological Therapy, 2011, 11, 211-224.	1.4	20
102	Synthesis of â€œDifficultâ€•Fluorescence Quenched Substrates of Granzyme C. International Journal of Peptide Research and Therapeutics, 2010, 16, 159-165.	0.9	5
103	Inflammatory Twins from PI3K Gang Brought to Justice?. Chemistry and Biology, 2010, 17, 101-102.	6.2	0
104	Identification of preferred carbohydrate binding modes in xenoreactive antibodies by combining conformational filters and binding site maps. Glycobiology, 2010, 20, 724-735.	1.3	25
105	Binding Mode Prediction of PDE4 Inhibitors: A Comparison of Modelling Methods. Australian Journal of Chemistry, 2010, 63, 396.	0.5	3
106	Structureâ^'Activity Relationships of Polymyxin Antibiotics. Journal of Medicinal Chemistry, 2010, 53, 1898-1916.	2.9	604
107	Phenylalanine-544 Plays a Key Role in Substrate and Inhibitor Binding by Providing a Hydrophobic Packing Point at the Active Site of Insulin-Regulated Aminopeptidase. Molecular Pharmacology, 2010, 78, 600-607.	1.0	21
108	Structure of granzyme C reveals an unusual mechanism of protease autoinhibition. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5587-5592.	3.3	25

#	Article	IF	Citations
109	The Structure of the Bacterial Oxidoreductase Enzyme DsbA in Complex with a Peptide Reveals a Basis for Substrate Specificity in the Catalytic Cycle of DsbA Enzymes. Journal of Biological Chemistry, 2009, 284, 17835-17845.	1.6	62
110	In silico analysis of antibodyâ€“carbohydrate interactions and its application to xenoreactive antibodies. Molecular Immunology, 2009, 47, 233-246.	1.0	31
111	Solid Phase Synthesis and Circular Dichroism Analysis of (i â†'ÂiÂ+Â4) Cyclic Lactam Analogues of Kisspeptin. International Journal of Peptide Research and Therapeutics, 2008, 14, 323-331.	0.9	2
112	Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neuroscience, 2008, 9, S14.	0.8	56
113	Structural and Biochemical Characterization of the Oxidoreductase NmDsbA3 from Neisseria meningitidis. Journal of Biological Chemistry, 2008, 283, 32452-32461.	1.6	23
114	Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochemical Journal, 2008, 414, 383-390.	1.7	49
115	Editorial [Hot Topic : Viagras Cousins - Towards a New Generation of Phosphodiesterase Inhibitors (Guest Editor: Philip Thompson)]. Current Topics in Medicinal Chemistry, 2007, 7, 389-389.	1.0	0
116	Re-Discovering PDE3 Inhibitors - New Opportunities for a Long Neglected Target. Current Topics in Medicinal Chemistry, 2007, 7, 421-436.	1.0	73
117	Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 969-973.	1.0	8
118	The major human and mouse granzymes are structurally and functionally divergent. Journal of Cell Biology, 2006, 175, 619-630.	2.3	187
119	Identification of a unique filamin A binding region within the cytoplasmic domain of glycoprotein Ibα. Biochemical Journal, 2005, 387, 849-858.	1.7	37
120	PI 3-kinase p110β: a new target for antithrombotic therapy. Nature Medicine, 2005, 11, 507-514.	15.2	555
121	The Next Generation of Phosphodiesterase Inhibitors: Structural Clues to Ligand and Substrate Selectivity of Phosphodiesterases. ChemInform, 2005, 36, no.	0.1	0
122	A reversed-phase HPLC-based method for the assay of cyclic nucleotide phosphodiesterase activity. Analytical Biochemistry, 2005, 339, 185-187.	1.1	2
123	The Next Generation of Phosphodiesterase Inhibitors:Â Structural Clues to Ligand and Substrate Selectivity of Phosphodiesterases. Journal of Medicinal Chemistry, 2005, 48, 3449-3462.	2.9	121
124	PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2847-2851.	1.0	25
125	Synthetic Studies of the Phosphatidylinositol 3-Kinase Inhibitor LY294002 and Related Analogues. Australian Journal of Chemistry, 2003, 56, 1099.	0.5	14
126	RhoA Sustains Integrin αIIbβ3Adhesion Contacts under High Shear. Journal of Biological Chemistry, 2002, 277, 14738-14746.	1.6	59

#	Article	IF	Citations
127	Solid-phase synthesis of a dendritic peptide related to a retinoblastoma protein fragment utilizing a combined boc- and fmoc-chemistry approach. Journal of Peptide Science, 2001, 7, 262-269.	0.8	6
128	Solid-phase synthesis of cyclic analogues related to the hypoglycaemic peptide hGH[6-13]: Comparison of twoi?i+4 lactam cyclization procedures. Journal of Peptide Science, 2001, 7, 529-536.	0.8	2
129	Importance of the P4â€² Residue in Human Granzyme B Inhibitors and Substrates Revealed by Scanning Mutagenesis of the Proteinase Inhibitor 9 Reactive Center Loop. Journal of Biological Chemistry, 2001, 276, 15177-15184.	1.6	68
130	Monoclonal antibody screening of a phage-displayed random peptide library reveals mimotopes of chemokine receptor CCR5: implications for the tertiary structure of the receptor and for an N-terminal binding site for HIV-1 gp120. European Journal of Immunology, 2000, 30, 1162-1171.	1.6	25
131	Evidence for the activation of PAR-2 by the sperm protease, acrosin: expression of the receptor on oocytes. FEBS Letters, 2000, 484, 285-290.	1.3	46
132	Title is missing!. International Journal of Peptide Research and Therapeutics, 1999, 6, 185-192.	0.1	0
133	Use of synthetic peptides to delineate discontinuous sequence regions involved in epitope sites of the thyrotropin Î²-subunit. International Journal of Peptide Research and Therapeutics, 1999, 6, 185-192.	0.1	2
134	Solid phase synthesis of cyclic peptides: model studies involvingiâˆ'(i+4) side chain-to-side chain cyclisation. , 1998, 4, 335-343.		13
135	Tropane-based amino acids for peptide structure-function studies: Inhibitors of platelet aggregation. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2699-2704.	1.0	12
136	Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R fromPorphyromonas gingivalis. FEBS Letters, 1998, 435, 45-48.	1.3	150
137	Comparison of the binding of Î±â€helical and Î²â€sheet peptides to a hydrophobic surface. Chemical Biology and Drug Design, 1998, 51, 401-412.	1.2	30
138	Fmoc-protected tropane-based amino acids for peptide structure-function studies. Tetrahedron Letters, 1997, 38, 2907-2910.	0.7	7
139	Conformational stability of a type II'Î²â€turn motif in human growth hormone [6â€“13] peptide analogues at hydrophobic surfaces. Chemical Biology and Drug Design, 1997, 49, 394-403.	1.2	12
140	Conformational analysis of human growth hormone [6â€13] peptide analogues. International Journal of Peptide and Protein Research, 1996, 48, 1-11.	0.1	7
141	Synthesis of ?-aminosuccinimide-containing peptides in Fmoc-based SPPS. International Journal of Peptide Research and Therapeutics, 1995, 1, 263-268.	0.1	6
142	A simple and inexpensive sample-handling method for the semi-preparative RP-HPLC of polypeptides and non-polar peptide derivatives: pre-adsorption of samples. Journal of Proteomics, 1995, 30, 153-161.	2.4	7
143	Synthesis of peptide amides using Fmocâ€based solidâ€phase procedures on 4â€methylbenzhydrylamine resins. International Journal of Peptide and Protein Research, 1995, 46, 174-180.	0.1	18
144	Quantitative Structure-activity Relationships Of (+)-anatoxin-a Derivatives. Natural Product Research, 1994, 4, 121-128.	0.4	4

#	Article	IF	Citations
145	Hypoglycaemic activity of an analogue of human growth hormone [6-13] incorporating a d-ala-pro dipeptide unit. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 1625-1628.	1.0	13
146	Conformational studies on (+)-anatoxin-a and derivatives. Journal of Computer-Aided Molecular Design, 1992, 6, 287-298.	1.3	14
147	Structural modification of anatoxin-a. Synthesis of model affinity ligands for the nicotinic acetylcholine receptor. Journal of the Chemical Society Chemical Communications, 1991, , 243.	2.0	13